The following is a summary of the Sanara MedTech Inc. (SMTI) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Sanara MedTech reported a Q3 2024 net revenue of $21.7 million, an increase of 35% year-over-year, marking its 12th consecutive record revenue quarter.

• Adjusted EBITDA improved to $800,000 in Q3 2024 from $300,000 in Q3 2023.

• The company experienced a net loss of $2.9 million in Q3 2024 due to higher SG&A costs, increased interest expenses, and expenses related to change in the fair value of earn-out liabilities.

Business Progress:

• Continued strategic investment in THP technology for expected mid-2025 commercial launch.

• Entered into a $5 million investment and exclusive U.S. distribution agreement with ChemoMouthpiece LLC, aligning well with Sanara's wound and skin care strategy.

• Soft tissue product sales increased to $18.9 million and bone fusion products rose to $2.8 million in Q3 2024.

• Surgical products now sold in over 1200 hospitals, with selling agreements expanding.

• Strengthened R&D, focusing on CellerateRX.

Opportunities:

• Emphasized growth potential for non-acute wound care with THP value-based strategy set for mid-2025 launch.

• Exploring mergers, acquisitions, and strategic partnerships to enhance surgical offerings and market reach.

Risks:

• Possible challenges in quickly achieving Profitability due to necessary ramp-up once Tissue Health Plus launches.

• Dependency on strategic and financial partners for successful execution and scaling of operations.

More details: Sanara MedTech IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.